Homocysteine and levodopa: Should Parkinson disease patients receive preventative therapy?

Neurology

Volumn 63, Issue 5, 2004, Pages 886-891

  Postuma, Ronald B ^a   Lang, Anthony E ^a  

^a TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ADENOSYLHOMOCYSTEINASE; CATECHOL METHYLTRANSFERASE INHIBITOR; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; PYRIDOXINE;

AMINO ACID METABOLISM; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY RISK; DEMENTIA; DNA POLYMORPHISM; DOPAMINE METABOLISM; DRUG COST; DRUG SAFETY; DYSKINESIA; EPIDEMIOLOGICAL DATA; HEART DISEASE; HUMAN; HYPERHOMOCYSTEINEMIA; MOTOR DYSFUNCTION; NERVE DEGENERATION; NEUROTOXICITY; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SECONDARY PREVENTION; SIDE EFFECT; STROKE; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL;

EID: 4644368806     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000137886.74175.5A     Document Type: Article

References (56)

1. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-2031.
2. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C→T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002;59:529-536.
3. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
4. Schnyder G, Roffi M, Flammer Y, Pin R, Hess OM. Effect of homocysteine-lowering therapy with folic acid, vitamin B(12), and vitamin B(6) on clinical outcome after percutaneous coronary intervention: the Swiss Heart study: a randomized controlled trial. JAMA 2002;288:973-979.
5. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002;346:476-483.
6. Vermeer SE, van Dijk EJ, Koudstaal PJ, et al. Homocysteine, silent brain infarcts, and white matter lesions: The Rotterdam Scan Study. Ann Neurol 2002;51:285-289.
7. Dufouil C, Alperovitch A, Ducros V, Tzourio C. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. Ann Neurol 2003;53:214-221.
8. den Heijer T, Vermeer SE, Clarke R, et al. Homocysteine and brain atrophy on MRI of non-demented elderly. Brain 2003;126(Pt 1):170-175.
9. Allain P, Le Bouil A, Cordillet E, Le Quay L, Bagheri H, Montastruc JL. Sulfate and cysteine levels in the plasma of patients with Parkinson's disease. Neurotoxicology 1995;16:527-529.
10. Kuhn W, Roebroek R, Blom H, et al. Elevated plasma levels of homocysteine in Parkinson's disease. Eur Neurol 1998;40:225-227.
11. Kuhn W, Roebroek R, Blom H, van Oppenraaij D, Muller T. Hyperhomocysteinaemia in Parkinson's disease. J Neurol 1998;245:811-812.
12. Blandini F, Fancellu R, Martignoni E, et al. Plasma homocysteine and 1-dopa metabolism in patients with Parkinson disease. Clin Chem 2001;47:1102-1104.
13. Miller JW, Selhub J, Nadeau MR, Thomas CA, Feldman RG, Wolf PA. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology 2003;60:1125-1129.
14. Rogers JD, Sanchez-Saffon A, Frol AB, Diaz-Arrastia R. Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease. Arch Neurol 2003;60:59-64.
15. Muller T, Woitalla D, Hauptmann B, Fowler B, Kuhn W. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease. Neurosci Lett 2001;308:54-56.
16. Muller T, Woitalla D, Fowler B, Kuhn W. 3-OMD and homocysteine plasma levels in parkinsonian patients. J Neural Transm 2002;109:175-179.
17. Yasui K, Kowa H, Nakaso K, Takeshima T, Nakashima K. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2000;55:437-440.
18. Yasui K, Nakaso K, Kowa H, Takeshima T, Nakashima K. Levodopa-induced hyperhomocysteinaemia in Parkinson's disease. Acta Neurol Scand 2003;108:66-67.
19. Morris MS. Homocysteine and Alzheimer's disease. Lancet Neurol 2003;2:425-428.
20. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH. The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Engl J Med 1999;340:1449-1454.
21. Malinow MR, Duell PB, Hess DL, et al. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N Engl J Med 1998;338:1009-1015.
22. Quinlivan EP, McPartlin J, McNulty H, et al. Importance of both folic acid and vitamin B12 in reduction of risk of vascular disease. Lancet 2002;359:227-228.
23. Cappuccio FP, Bell R, Perry IJ, et al. Homocysteine levels in men and women of different ethnic and cultural background living in England. Atherosclerosis 2002;164:95-102.
24. Wald DS, Bishop L, Wald NJ, et al. Randomized trial of folic acid supplementation and serum homocysteine levels. Arch Intern Med 2001;161:695-700.
25. Spence JD, Howard VJ, Chambless LE, et al. Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design. Neuroepidemiology 2001;20:16-25.
26. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-575.
27. The VITATOPS (Vitamins to Prevent Stroke) Trial: rationale and design of an international, large, simple, randomised trial of homocysteine-lowering multivitamin therapy in patients with recent transient ischaemic attack or stroke. Cerebrovasc Dis 2002;13:120-126.
28. Kalaria RN. Small vessel disease and Alzheimer's dementia: pathological considerations. Cerebrovasc Dis 2002;13(suppl 2):48-52.
29. Lawrence de Koning AB, Werstuck GH, Zhou J, Austin RC. Hyperhomocysteinemia and its role in the development of atherosclerosis. Clin Biochem 2003;36:431-441.
30. Cook JW, Taylor LM, Orloff SL, Landry GJ, Moneta GL, Porter JM. Homocysteine and arterial disease. Experimental mechanisms. Vascul Pharmacol 2002;38:293-300.
31. Haynes WG. Hyperhomocysteinemia, vascular function and atherosclerosis: effects of vitamins. Cardiovasc Drugs Ther 2002;16:391-399.
32. Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Transm 2002;109:1445-1452.
33. Kuhn W, Hummel T, Woitalla D, Muller T. Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD. Neurology 2001;56:281-282.
34. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002;41:261-309.
35. Gorell JM, Johnson CC, Rybicki BA. Parkinson's disease and its comorbid disorders: an analysis of Michigan mortality data, 1970 to 1990. Neurology 1994;44:1865-1868.
36. Ben Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-299.
37. Nakaso K, Yasui K, Kowa H, et al. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype. J Neurol Sci 2003;207:19-23.
38. Levine RL, Jones JC, Bee N. Stroke and Parkinson's disease. Stroke 1992;23:839-842.
39. Marttila RJ, Rinne UK. Arteriosclerosis, heredity, and some previous infections in the etiology of Parkinson's disease. A case-control study. Clin Neurol Neurosurg 1976;79:46-56.
40. Mastaglia FL, Johnsen RD, Kakulas BA. Prevalence of stroke in Parkinson's disease: a postmortem study. Mov Disord 2002;17:772-774.
41. Jellinger KA. Prevalence of stroke in Parkinson's disease. Mov Disord 2003;18:723-724.
42. Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke? Mov Disord 2001;16:119-123.
43. McCann SJ, LeCouteur DG, Green AC, et al. The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology 1998;17:310-317.
44. Struck LK, Rodnitzky RL, Dobson JK. Stroke and its modification in Parkinson's disease. Stroke 1990;21:1395-1399.
45. Brevetti G, Bonaduce D, Breglio R, et al. Parkinson's disease and hypotension: 24-hour blood pressure recording in ambulant patients. Clin Cardiol 1990;13:474-478.
46. Hakamaki T, Rajala T, Lehtonen A. Ambulatory 24-hour blood pressure recordings in patients with Parkinson's disease with or without fludrocortisone. Int J Clin Pharmacol Ther 1998;36:367-369.
47. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet 2000;356:1955-1964.
48. Hernan MA, Takkouche B, Caamano-Isorna F, Gestal-Otero JJ. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol 2002;52:276-284.
49. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003;2:229-237.
50. Melamed E, Offen D, Shirvan A, Ziv I. Levodopa-an exotoxin or a therapeutic drug? J Neurol 2000;247(suppl 2):II135-II139.
51. LeWitt PA, Nyholm D. New developments in levodopa therapy. Neurology 2004;62(suppl 1):S9-S16.
52. Duan W, Ladenheim B, Cutler RG, Kruman II, Cadet JL, Mattson MP. Dietary folate deficiency and elevated homocysteine levels endanger dopaminergic neurons in models of Parkinson's disease. J Neurochem 2002;80:101-110.
53. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62(suppl 1):S47-S55.
54. Snodgrass SR. Vitamin neurotoxicity. Mol Neurobiol 1992;6:41-73.
55. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 1997;94:5923-5928.
56. Kruman II, Kumaravel TS, Lohani A, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci 2002;22:1752-1762.